^
    2d
    CA240-0008: [14C]-BMS986504 Mass Balance Study in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (2024-515518-41-00)
    P1, N=16, Recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P1 trial
    |
    navlimetostat (BMS-986504)
    3d
    Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor (clinicaltrials.gov)
    P1/2, N=17, Not yet recruiting, Ankit Mangla, MD | Initiation date: Apr 2026 --> Aug 2026
    Trial initiation date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    navlimetostat (BMS-986504)
    11d
    A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion (clinicaltrials.gov)
    P1, N=8, Recruiting, Bristol-Myers Squibb | Trial completion date: Apr 2026 --> Oct 2027 | Trial primary completion date: Apr 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    navlimetostat (BMS-986504)
    16d
    A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) (clinicaltrials.gov)
    P2/3, N=470, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    gemcitabine • albumin-bound paclitaxel • navlimetostat (BMS-986504)
    28d
    SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, University of Southampton
    New P2 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    navlimetostat (BMS-986504)
    1m
    BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion (clinicaltrials.gov)
    P1/2, N=72, Not yet recruiting, Northwestern University
    New P1/2 trial • Pan tumor
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    pemetrexed • navlimetostat (BMS-986504)
    1m
    A Phase 1 Study of Navlimetostat Tablet Formulations (clinicaltrials.gov)
    P1, N=64, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    navlimetostat (BMS-986504)
    1m
    Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=17, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MTAP (Methylthioadenosine Phosphorylase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    navlimetostat (BMS-986504) • pumitamig (BNT327)
    2ms
    Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. (PubMed, bioRxiv)
    Here, we investigated mechanisms of acquired resistance to the MTA-cooperative PRMT5 inhibitor BMS-986504/MRTX1719 in MTAP-null non-small cell lung cancer (NSCLC) cells and sought to identify therapeutic vulnerabilities that emerge upon resistance...Instead, resistance was associated with collateral sensitivity to MEK inhibition and enrichment of MAPK-related transcriptional programs. Together, these findings identify MEK inhibition as an actionable collateral vulnerability in MTAP-null NSCLC cells that acquire resistance to PRMT5 inhibition.
    Preclinical • Journal
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    navlimetostat (BMS-986504)
    2ms
    A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) (clinicaltrials.gov)
    P2/3, N=470, Recruiting, Bristol-Myers Squibb
    Trial initiation date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    gemcitabine • albumin-bound paclitaxel • navlimetostat (BMS-986504)
    2ms
    Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor (clinicaltrials.gov)
    P1/2, N=17, Not yet recruiting, Ankit Mangla, MD
    New P1/2 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    navlimetostat (BMS-986504)
    2ms
    A Phase 1 Study of Navlimetostat Tablet Formulations (clinicaltrials.gov)
    P1, N=64, Not yet recruiting, Bristol-Myers Squibb
    New P1 trial
    |
    navlimetostat (BMS-986504)